Prolyl hydroxylase inhibitors
AssigneeAerpio Therapeutics Inc.
InventorsJoseph H. Gardner, Robert Shalwitz
Life of this patent
Estimating the term…
Abstract
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1α), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.
Claims16
A compound having the formula:
- R4 is C1-C4 linear alkyl or C3-C4 branched alkyl;
- or
- a pharmaceutically acceptable salt thereof.
A compound chosen from:
- Methyl 4-((1-benzyl-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-{[1-(3-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl]methyl}piperazine-1-carboxylate;
- Methyl 4-((3-hydroxy-2-oxo-1-(phenylsulfonyl)-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- Ethyl 4-((3-hydroxy-2-oxo-1-(phenylsulfonyl)-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate;
- and
- tert-Butyl 4-((3-hydroxy-2-oxo-1-(phenylsulfonyl)-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate.
A method for treating an infection, comprising administering to a subject a composition comprising:
- a) one or more compounds having the formula:
- wherein R4 is C1-C4 linear alkyl or C3-C4 branched alkyl;
- or
- a pharmaceutically acceptable salt thereof;
- and
- b) one or more pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.